ReviewTherapeutic advances in cardiovascular disease

The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction.

Michael V Genuardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.